<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00700427</url>
  </required_header>
  <id_info>
    <org_study_id>9655</org_study_id>
    <secondary_id>B4Z-MC-LYDO</secondary_id>
    <nct_id>NCT00700427</nct_id>
  </id_info>
  <brief_title>A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>Maintenance of Response After Open-Label Treatment With Atomoxetine Hydrochloride in Adult Outpatients With Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      LYDO is a multi-center study that will enroll approximately 1925 adult outpatients with
      Attention Deficit/Hyperactivity Disorder (ADHD). Patients will receive, under open label
      conditions, atomoxetine up to 100 mg/day during the acute, open-label part of the study.
      Those patients that meet the response criteria will continue the blind phase of the study up
      to a year. During that period, patients that respond to atomoxetine will be randomized to
      continue the treatment with atomoxetine or with placebo (neither the patients nor
      investigators know if patients receive atomoxetine or placebo).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Maintain a Satisfactory Response During the Double-Blind Maintenance/Randomized Withdrawal Period</measure>
    <time_frame>Baseline (Week 24) up to Week 49</time_frame>
    <description>Conners' Adult ADHD Rating Scale-Investigator Rated:Screening Version (CAARS-Inv:SV); 30-item scale (3 subscales): inattention, hyperactivity/impulsivity (9 items each), ADHD Index (12 items). Each item is scored 0 (not at all/never) to 3 (very much/very frequently). Total ADHD symptoms score (SS)=inattention+hyperactivity/impulsivity (range:0-54). Higher score=more impairment. Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) measures participant's overall severity of ADHD symptoms and scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Maintenance of response during the randomized withdrawal phase was a reduction of ≥30% in the baseline CAARS-Inv:SV Total ADHD SS and a CGI-ADHD-S score ≤3. Participants had to continuously meet the response criteria, except for 1 excursion after assessment at Week 24 through Week 37 and 1 other excursion after assessment at Week 37 through Week 49. Excursions were not permitted at 2 consecutive visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Days Until Relapse</measure>
    <time_frame>Baseline (Week 24) up to Week 49</time_frame>
    <description>Relapse was defined as 2 consecutive visits with a CGI-ADHD-S score ≥4 points and a return to ≥80% of participant's baseline (Visit 2) CAARS-Inv:SV Total ADHD Symptom Score (SS). If the participant showed evidence of a return of symptoms at a single visit that met severity criteria described above, and because of worsening symptoms, was unwilling to remain in the study or did not return for a second visit, the participant was also considered to have relapsed.
CAARS-Inv:SV is a 30-item scale (3 subscales): Inattention, Hyperactivity/Impulsivity (9 items each), ADHD Index (12 items). Each item is scored 0 (0=not at all/never) to 3 (very much/very frequently). Total ADHD SS=inattention+hyperactivity/impulsivity (range: 0-54). Higher score=more impairment. CGI-ADHD-S measures participant's overall severity of ADHD symptoms and scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life (AAQoL) Scale From Week 24 to Week 49</measure>
    <time_frame>Baseline (Week 24), Week 49</time_frame>
    <description>The AAQoL is a self-reported, 29-item scale assessing functional impairments in adults with ADHD. Each item is rated on a 5-point Likert scale; range: 1 (Not at all/ Never) to 5 (Extremely/Very Often). 5-domains of scale include: work functioning, family relationships, social functioning, activities of daily living (driving, managing finances), and psychological adaptation (life satisfaction, self-esteem). These scores are transformed to a 0-100 point scale (1=0; 2=25; 3=50; 4=75; 5=100), and then the item scores are summed and divided by item count to generate overall scores. The overall scores have the same total range of scores of 0-100, with higher scores indicating better quality of life. Least Squares (LS) Mean values were adjusted for baseline AAQoL score and Investigator/site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Conner's Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (Observer Rated [CAARS-O:SV]) Total ADHD Symptom Score From Week 24 to Week 49</measure>
    <time_frame>Baseline (Week 24), Week 49</time_frame>
    <description>The CAARS-O:SV is a 30-item observer (typically a significant other or close friend) completed scale containing 3 subscales: inattention (9 items), hyperactivity/impulsivity (9 items), and ADHD Index (12 items). Each item is scored 0-3 (0=not at all/never; 1=just a little/once in a while; 2=pretty much/often; 3=very much/very frequently). Inattention and hyperactivity subscales range from 0-27; ADHD index subscale range is 0-36 with higher scores indicating more impaired participants. Total ADHD symptoms score=sum of the inattention and hyperactivity/impulsivity subscales, ranging from 0-54, with higher scores indicating more impaired participants. Least Squares (LS) Mean values adjusted for treatment, pooled Investigator, and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Conner's Adult ADHD Rating Scale-Self Rated (CARRS-S:SV) Total ADHD Symptom Score From Week 24 to Week 49</measure>
    <time_frame>Baseline (Week 24), Week 49</time_frame>
    <description>CAARS-S:SV is a 30-item participant completed scale containing 3 subscales: inattention (9 items), hyperactivity/impulsivity (9 items), ADHD Index (12 items). 0-3 (0=not at all/never; 1=just a little/once in a while; 2=pretty much/often; 3=very much/very frequently). Inattention and hyperactivity subscales range from 0-27; ADHD index subscale range is 0-36 with higher scores indicating more impaired participants. Total ADHD symptoms score=sum of the inattention and hyperactivity/impulsivity subscales; range: 0-54 with higher scores indicating more impaired participants. Least Squares (LS) Mean values adjusted for treatment, pooled Investigator, and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version: Self Report (BRIEF-A:Self Report) Global Executive Composite (GEC) Index Score From Week 24 to Week 49</measure>
    <time_frame>Baseline (Week 24), Week 49</time_frame>
    <description>The BRIEF-A:Self Report is a 75-item self-reported measure captures adults' views of their own executive functions/self-regulation in their everyday environment. Items include: Inhibit, Shift, Emotional Control, Self Monitor, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials. Behavior is rated on a 3-point scale: 1 (behavior is never observed) to 3 (behavior is often observed). GEC Index Score is a subscore of the 75-item BRIEF-A score, reflects overall functioning and was calculated based on 70 items. Total scores range: 70-210. Lower scores = less perceived impairment. Least Squares (LS) Mean values were adjusted for treatment, pooled Investigator, and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version:Informant Report (BRIEF-A:Informant) Global Executive Composite (GEC) Index Score From Week 24 to Week 49</measure>
    <time_frame>Baseline (Week 24), Week 49</time_frame>
    <description>BRIEF-A:Informant is a 75-item third-party observer's view of the participants' executive functions/self-regulation in their everyday environment. Items include: Inhibit, Shift, Emotional Control, Self Monitor, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials. Behavior is rated on a 3-point scale: 1 (behavior is never observed) to 3 (behavior is often observed). GEC Index Score is a subscore of the 75-item BRIEF-A score, reflects overall functioning and was calculated based on 70 items. Total scores range: 70-210. Lower scores = less perceived impairment. Least Squares (LS) Mean values were adjusted for treatment, pooled Investigator, and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Quality of Life (EuroQoL) Questionnaire-5 Dimensions (EQ-5D) Index Score From Week 24 to Week 49</measure>
    <time_frame>Baseline (Week 24), Week 49</time_frame>
    <description>The EQ-5D is a Self-reported, 5-item scale to assess health utility (mobility, self-care, usual activities, pain and discomfort, and depression/anxiety). Scoring is on a 3-point scale (1=no health problems, 2=some or moderate problems, 3=major health problems). A preference value Index score is calculated using societal preference developed from a general population-based valuation studies. Index score ranges: United Kingdom (UK): -0.59 to 1.0, United States (US): -0.11 to 1.0, where 1 represents best possible health and 0 represents dead, with &lt;0 interpreted as a health state &quot;worse than dead.&quot; A Quality of Life Health State Score visual analog scale (VAS) was assessed, scores range from 0 to 100. Higher scores indicate better health state. Least Square (LS) Mean values were adjusted for treatment, pooled Investigator, baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2017</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Atomoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atomoxetine 40-100 milligrams per day (mg/day) orally, once daily or twice daily for 24 weeks, followed by atomoxetine 80-100 mg/day orally, once daily or twice daily for 25 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Atomoxetine 40-100 mg/day orally, once daily or twice daily for 24 weeks, followed by placebo orally, once daily for 25 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atomoxetine hydrochloride</intervention_name>
    <description>Oral 40-100 mg/day</description>
    <arm_group_label>Atomoxetine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Strattera</other_name>
    <other_name>LY139603</other_name>
    <other_name>atomoxetine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral delivery of matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults

          -  Male or female

          -  Must meet Attention-Deficit/Hyperactivity Disorder (ADHD) according to Diagnostic and
             Statistical Manual of Mental Disorders, Fourth Edition Text Revision™ (DSM-IV-TR™)
             criteria

        Exclusion Criteria:

          -  Comorbidity with major psychiatric disorder

          -  Clinically significant depression or anxiety

          -  Patients with significant medical conditions

          -  Current alcohol/drugs abuse/dependence

          -  Concomitant excluded medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 am - 5 pm Eastern Time (UTC/GMT - 5hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vienna</city>
        <zip>A1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brugge</city>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kortenberg</city>
        <zip>3070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mechelen</city>
        <zip>2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Uccle</city>
        <zip>1180</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Helsinki</city>
        <zip>00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Douai</city>
        <zip>59500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orvault</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ahrensburg</city>
        <zip>22926</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>D-14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ellwangen</city>
        <zip>73479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Essen</city>
        <zip>D-45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Freiburg</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fulda</city>
        <zip>36037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hadamar</city>
        <zip>65589</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hagen</city>
        <zip>58093</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leipzig</city>
        <zip>04157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67071</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Munich</city>
        <zip>80333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wurzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coppito</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milano</city>
        <zip>20121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Donà Di Piave</city>
        <zip>30027</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Amersfoort</city>
        <zip>3816 CP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hengelo</city>
        <zip>7555 DL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tilburg</city>
        <zip>5037 SK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vlissingen</city>
        <zip>4382 EE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cascais</city>
        <zip>2750-782</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coimbra</city>
        <zip>3030</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alcorcon</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zamora</city>
        <zip>49021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lulea</city>
        <zip>SE 972 35</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lund</city>
        <zip>22361</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malmo</city>
        <zip>21135</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vaxjo</city>
        <zip>SE 351 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lausanne</city>
        <zip>1005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brighton</city>
        <state>East Sussex</state>
        <zip>BN1 3RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Storrington</city>
        <state>West Sussex</state>
        <zip>RH20 4NQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <zip>SE5 8AZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2008</study_first_submitted>
  <study_first_submitted_qc>June 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <results_first_submitted>August 23, 2012</results_first_submitted>
  <results_first_submitted_qc>April 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2013</results_first_posted>
  <last_update_submitted>June 12, 2014</last_update_submitted>
  <last_update_submitted_qc>June 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Adult</keyword>
  <keyword>long term</keyword>
  <keyword>maintenance of response</keyword>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study consisted of 4 treatment periods: 12 weeks open-label, acute-treatment (trx) phase (Study Period 2), 12 weeks double-blind maintenance phase of Study Period 3 (Study Period 3A), 25 weeks double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B) and an Open-Label Extension Period (Study Period 4) lasting up to 2.3 years.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atomoxetine (Study Period 2)</title>
          <description>40-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 12 weeks during open-label, acute-treatment phase (Study Period 2).</description>
        </group>
        <group group_id="P2">
          <title>Atomoxetine (Study Period 3A)</title>
          <description>40-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 12 weeks during double-blind randomized withdrawal phase (Study Period 3).</description>
        </group>
        <group group_id="P3">
          <title>Atomoxetine (Study Period 3B)</title>
          <description>80-100 mg/day atomoxetine orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
        </group>
        <group group_id="P4">
          <title>Placebo (Study Period 3B)</title>
          <description>Placebo orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
        </group>
        <group group_id="P5">
          <title>Atomoxetine (Study Period 4)</title>
          <description>Participants who received either atomoxetine or placebo and completed the last visit of Study Period 3 who were in countries where the adult ADHD indication for atomoxetine was not approved were allowed to participant in Study Period 4 (Open-label Extension). Participants received 40 mg/day atomoxetine orally for at least 7 days after which it was increased to 80-100 mg/day atomoxetine orally for up to 2.3 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Study Period 2 (Open-Label Acute Trx)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2017"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="2011"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1006">One participant was mistakenly recorded as completed. The reason for discontinuation is unknown.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1011"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="298"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Interim Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Relapse</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Period 3A (Blinded Maintenance)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1005"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="524"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="481"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Interim Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing - Not Otherwise Defined</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Period 3B (Randomized Withdrawal)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="266"/>
                <participants group_id="P4" count="258"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="184"/>
                <participants group_id="P4" count="165"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="93"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Interim Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Period 4 (Open-Label Extension)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Atomoxetine (40-100 mg)</title>
          <description>40-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 12 weeks during open-label, acute-treatment period (Study Period 2).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2017"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.15" spread="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>West Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Maintain a Satisfactory Response During the Double-Blind Maintenance/Randomized Withdrawal Period</title>
        <description>Conners' Adult ADHD Rating Scale-Investigator Rated:Screening Version (CAARS-Inv:SV); 30-item scale (3 subscales): inattention, hyperactivity/impulsivity (9 items each), ADHD Index (12 items). Each item is scored 0 (not at all/never) to 3 (very much/very frequently). Total ADHD symptoms score (SS)=inattention+hyperactivity/impulsivity (range:0-54). Higher score=more impairment. Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) measures participant's overall severity of ADHD symptoms and scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Maintenance of response during the randomized withdrawal phase was a reduction of ≥30% in the baseline CAARS-Inv:SV Total ADHD SS and a CGI-ADHD-S score ≤3. Participants had to continuously meet the response criteria, except for 1 excursion after assessment at Week 24 through Week 37 and 1 other excursion after assessment at Week 37 through Week 49. Excursions were not permitted at 2 consecutive visits.</description>
        <time_frame>Baseline (Week 24) up to Week 49</time_frame>
        <population>Primary outcome measure analysis was conducted using all randomized participants in the Double-Blind Maintenance/Randomized Withdrawal Period (Study Period 3B).</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>80-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Maintain a Satisfactory Response During the Double-Blind Maintenance/Randomized Withdrawal Period</title>
          <description>Conners' Adult ADHD Rating Scale-Investigator Rated:Screening Version (CAARS-Inv:SV); 30-item scale (3 subscales): inattention, hyperactivity/impulsivity (9 items each), ADHD Index (12 items). Each item is scored 0 (not at all/never) to 3 (very much/very frequently). Total ADHD symptoms score (SS)=inattention+hyperactivity/impulsivity (range:0-54). Higher score=more impairment. Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) measures participant's overall severity of ADHD symptoms and scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Maintenance of response during the randomized withdrawal phase was a reduction of ≥30% in the baseline CAARS-Inv:SV Total ADHD SS and a CGI-ADHD-S score ≤3. Participants had to continuously meet the response criteria, except for 1 excursion after assessment at Week 24 through Week 37 and 1 other excursion after assessment at Week 37 through Week 49. Excursions were not permitted at 2 consecutive visits.</description>
          <population>Primary outcome measure analysis was conducted using all randomized participants in the Double-Blind Maintenance/Randomized Withdrawal Period (Study Period 3B).</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Until Relapse</title>
        <description>Relapse was defined as 2 consecutive visits with a CGI-ADHD-S score ≥4 points and a return to ≥80% of participant's baseline (Visit 2) CAARS-Inv:SV Total ADHD Symptom Score (SS). If the participant showed evidence of a return of symptoms at a single visit that met severity criteria described above, and because of worsening symptoms, was unwilling to remain in the study or did not return for a second visit, the participant was also considered to have relapsed.
CAARS-Inv:SV is a 30-item scale (3 subscales): Inattention, Hyperactivity/Impulsivity (9 items each), ADHD Index (12 items). Each item is scored 0 (0=not at all/never) to 3 (very much/very frequently). Total ADHD SS=inattention+hyperactivity/impulsivity (range: 0-54). Higher score=more impairment. CGI-ADHD-S measures participant's overall severity of ADHD symptoms and scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).</description>
        <time_frame>Baseline (Week 24) up to Week 49</time_frame>
        <population>Analyses were conducted using all randomized participants in the Double-Blind Period (Study Period 3B).</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>80-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Until Relapse</title>
          <description>Relapse was defined as 2 consecutive visits with a CGI-ADHD-S score ≥4 points and a return to ≥80% of participant's baseline (Visit 2) CAARS-Inv:SV Total ADHD Symptom Score (SS). If the participant showed evidence of a return of symptoms at a single visit that met severity criteria described above, and because of worsening symptoms, was unwilling to remain in the study or did not return for a second visit, the participant was also considered to have relapsed.
CAARS-Inv:SV is a 30-item scale (3 subscales): Inattention, Hyperactivity/Impulsivity (9 items each), ADHD Index (12 items). Each item is scored 0 (0=not at all/never) to 3 (very much/very frequently). Total ADHD SS=inattention+hyperactivity/impulsivity (range: 0-54). Higher score=more impairment. CGI-ADHD-S measures participant's overall severity of ADHD symptoms and scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).</description>
          <population>Analyses were conducted using all randomized participants in the Double-Blind Period (Study Period 3B).</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The mean and standard deviation could not be reliably estimated because of low numbers of participants who relapsed.</measurement>
                    <measurement group_id="O2" value="NA">The mean and standard deviation could not be reliably estimated because of low numbers of participants who relapsed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life (AAQoL) Scale From Week 24 to Week 49</title>
        <description>The AAQoL is a self-reported, 29-item scale assessing functional impairments in adults with ADHD. Each item is rated on a 5-point Likert scale; range: 1 (Not at all/ Never) to 5 (Extremely/Very Often). 5-domains of scale include: work functioning, family relationships, social functioning, activities of daily living (driving, managing finances), and psychological adaptation (life satisfaction, self-esteem). These scores are transformed to a 0-100 point scale (1=0; 2=25; 3=50; 4=75; 5=100), and then the item scores are summed and divided by item count to generate overall scores. The overall scores have the same total range of scores of 0-100, with higher scores indicating better quality of life. Least Squares (LS) Mean values were adjusted for baseline AAQoL score and Investigator/site.</description>
        <time_frame>Baseline (Week 24), Week 49</time_frame>
        <population>All randomized participants with a baseline and at least 1 post-baseline AAQoL score were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>80-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life (AAQoL) Scale From Week 24 to Week 49</title>
          <description>The AAQoL is a self-reported, 29-item scale assessing functional impairments in adults with ADHD. Each item is rated on a 5-point Likert scale; range: 1 (Not at all/ Never) to 5 (Extremely/Very Often). 5-domains of scale include: work functioning, family relationships, social functioning, activities of daily living (driving, managing finances), and psychological adaptation (life satisfaction, self-esteem). These scores are transformed to a 0-100 point scale (1=0; 2=25; 3=50; 4=75; 5=100), and then the item scores are summed and divided by item count to generate overall scores. The overall scores have the same total range of scores of 0-100, with higher scores indicating better quality of life. Least Squares (LS) Mean values were adjusted for baseline AAQoL score and Investigator/site.</description>
          <population>All randomized participants with a baseline and at least 1 post-baseline AAQoL score were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.12"/>
                    <measurement group_id="O2" value="-4.0" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Conner's Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (Observer Rated [CAARS-O:SV]) Total ADHD Symptom Score From Week 24 to Week 49</title>
        <description>The CAARS-O:SV is a 30-item observer (typically a significant other or close friend) completed scale containing 3 subscales: inattention (9 items), hyperactivity/impulsivity (9 items), and ADHD Index (12 items). Each item is scored 0-3 (0=not at all/never; 1=just a little/once in a while; 2=pretty much/often; 3=very much/very frequently). Inattention and hyperactivity subscales range from 0-27; ADHD index subscale range is 0-36 with higher scores indicating more impaired participants. Total ADHD symptoms score=sum of the inattention and hyperactivity/impulsivity subscales, ranging from 0-54, with higher scores indicating more impaired participants. Least Squares (LS) Mean values adjusted for treatment, pooled Investigator, and baseline.</description>
        <time_frame>Baseline (Week 24), Week 49</time_frame>
        <population>Participants with a non-missing baseline and at least 1 post-baseline CAARS-O:SV result within each group, Last Observation Carried Forward (LOCF) were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>80-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Conner's Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (Observer Rated [CAARS-O:SV]) Total ADHD Symptom Score From Week 24 to Week 49</title>
          <description>The CAARS-O:SV is a 30-item observer (typically a significant other or close friend) completed scale containing 3 subscales: inattention (9 items), hyperactivity/impulsivity (9 items), and ADHD Index (12 items). Each item is scored 0-3 (0=not at all/never; 1=just a little/once in a while; 2=pretty much/often; 3=very much/very frequently). Inattention and hyperactivity subscales range from 0-27; ADHD index subscale range is 0-36 with higher scores indicating more impaired participants. Total ADHD symptoms score=sum of the inattention and hyperactivity/impulsivity subscales, ranging from 0-54, with higher scores indicating more impaired participants. Least Squares (LS) Mean values adjusted for treatment, pooled Investigator, and baseline.</description>
          <population>Participants with a non-missing baseline and at least 1 post-baseline CAARS-O:SV result within each group, Last Observation Carried Forward (LOCF) were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADHD Imputed (Attributed) Index Score (N=164, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.60" spread="0.56"/>
                    <measurement group_id="O2" value="-0.10" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperactivity/Impulsivity Subscale Imputed Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.90" spread="0.44"/>
                    <measurement group_id="O2" value="-0.10" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inattention Subscale Imputed Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.60" spread="0.46"/>
                    <measurement group_id="O2" value="-0.10" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ADHD Symptom Imputed Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.50" spread="0.83"/>
                    <measurement group_id="O2" value="-0.40" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for ADHD Imputed (Attributed) Index Score.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value for Hyperactivity/Impulsivity Subscale Imputed Score.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>P-value for Inattention Subscale Imputed Score.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value for Total ADHD Symptom Imputed Score.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Conner's Adult ADHD Rating Scale-Self Rated (CARRS-S:SV) Total ADHD Symptom Score From Week 24 to Week 49</title>
        <description>CAARS-S:SV is a 30-item participant completed scale containing 3 subscales: inattention (9 items), hyperactivity/impulsivity (9 items), ADHD Index (12 items). 0-3 (0=not at all/never; 1=just a little/once in a while; 2=pretty much/often; 3=very much/very frequently). Inattention and hyperactivity subscales range from 0-27; ADHD index subscale range is 0-36 with higher scores indicating more impaired participants. Total ADHD symptoms score=sum of the inattention and hyperactivity/impulsivity subscales; range: 0-54 with higher scores indicating more impaired participants. Least Squares (LS) Mean values adjusted for treatment, pooled Investigator, and baseline.</description>
        <time_frame>Baseline (Week 24), Week 49</time_frame>
        <population>Participants with a non-missing baseline and at least 1 post-baseline CAARS-S:SV result within each treatment group, Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>80-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Conner's Adult ADHD Rating Scale-Self Rated (CARRS-S:SV) Total ADHD Symptom Score From Week 24 to Week 49</title>
          <description>CAARS-S:SV is a 30-item participant completed scale containing 3 subscales: inattention (9 items), hyperactivity/impulsivity (9 items), ADHD Index (12 items). 0-3 (0=not at all/never; 1=just a little/once in a while; 2=pretty much/often; 3=very much/very frequently). Inattention and hyperactivity subscales range from 0-27; ADHD index subscale range is 0-36 with higher scores indicating more impaired participants. Total ADHD symptoms score=sum of the inattention and hyperactivity/impulsivity subscales; range: 0-54 with higher scores indicating more impaired participants. Least Squares (LS) Mean values adjusted for treatment, pooled Investigator, and baseline.</description>
          <population>Participants with a non-missing baseline and at least 1 post-baseline CAARS-S:SV result within each treatment group, Last Observation Carried Forward (LOCF).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADHD Symptom Imputed Index Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="0.44"/>
                    <measurement group_id="O2" value="0.90" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperactivity-Impulsivity Subscale Imputed Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="0.33"/>
                    <measurement group_id="O2" value="0.50" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inattention Subscale Imputed Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.38"/>
                    <measurement group_id="O2" value="1.20" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ADHD Symptom Imputed Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.60" spread="0.65"/>
                    <measurement group_id="O2" value="1.70" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for ADHD Imputed (Attributed) Index Score.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Hyperactivity/Impulsivity Subscale Imputed Score.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Inattention Subscale Imputed Score.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Total ADHD Symptom Imputed Score.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version: Self Report (BRIEF-A:Self Report) Global Executive Composite (GEC) Index Score From Week 24 to Week 49</title>
        <description>The BRIEF-A:Self Report is a 75-item self-reported measure captures adults' views of their own executive functions/self-regulation in their everyday environment. Items include: Inhibit, Shift, Emotional Control, Self Monitor, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials. Behavior is rated on a 3-point scale: 1 (behavior is never observed) to 3 (behavior is often observed). GEC Index Score is a subscore of the 75-item BRIEF-A score, reflects overall functioning and was calculated based on 70 items. Total scores range: 70-210. Lower scores = less perceived impairment. Least Squares (LS) Mean values were adjusted for treatment, pooled Investigator, and baseline.</description>
        <time_frame>Baseline (Week 24), Week 49</time_frame>
        <population>Participants with a non-missing baseline and at least 1 post-baseline BRIEF-A:Self Report result within each group, Last Observation Carried Forward (LOCF) were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>80-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version: Self Report (BRIEF-A:Self Report) Global Executive Composite (GEC) Index Score From Week 24 to Week 49</title>
          <description>The BRIEF-A:Self Report is a 75-item self-reported measure captures adults' views of their own executive functions/self-regulation in their everyday environment. Items include: Inhibit, Shift, Emotional Control, Self Monitor, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials. Behavior is rated on a 3-point scale: 1 (behavior is never observed) to 3 (behavior is often observed). GEC Index Score is a subscore of the 75-item BRIEF-A score, reflects overall functioning and was calculated based on 70 items. Total scores range: 70-210. Lower scores = less perceived impairment. Least Squares (LS) Mean values were adjusted for treatment, pooled Investigator, and baseline.</description>
          <population>Participants with a non-missing baseline and at least 1 post-baseline BRIEF-A:Self Report result within each group, Last Observation Carried Forward (LOCF) were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.70" spread="1.88"/>
                    <measurement group_id="O2" value="0.90" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version:Informant Report (BRIEF-A:Informant) Global Executive Composite (GEC) Index Score From Week 24 to Week 49</title>
        <description>BRIEF-A:Informant is a 75-item third-party observer’s view of the participants’ executive functions/self-regulation in their everyday environment. Items include: Inhibit, Shift, Emotional Control, Self Monitor, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials. Behavior is rated on a 3-point scale: 1 (behavior is never observed) to 3 (behavior is often observed). GEC Index Score is a subscore of the 75-item BRIEF-A score, reflects overall functioning and was calculated based on 70 items. Total scores range: 70-210. Lower scores = less perceived impairment. Least Squares (LS) Mean values were adjusted for treatment, pooled Investigator, and baseline.</description>
        <time_frame>Baseline (Week 24), Week 49</time_frame>
        <population>Participants with a non-missing baseline and at least 1 post-baseline BRIEF-A:Informant result within each group, Last Observation Carried Forward (LOCF) were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>80-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version:Informant Report (BRIEF-A:Informant) Global Executive Composite (GEC) Index Score From Week 24 to Week 49</title>
          <description>BRIEF-A:Informant is a 75-item third-party observer’s view of the participants’ executive functions/self-regulation in their everyday environment. Items include: Inhibit, Shift, Emotional Control, Self Monitor, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials. Behavior is rated on a 3-point scale: 1 (behavior is never observed) to 3 (behavior is often observed). GEC Index Score is a subscore of the 75-item BRIEF-A score, reflects overall functioning and was calculated based on 70 items. Total scores range: 70-210. Lower scores = less perceived impairment. Least Squares (LS) Mean values were adjusted for treatment, pooled Investigator, and baseline.</description>
          <population>Participants with a non-missing baseline and at least 1 post-baseline BRIEF-A:Informant result within each group, Last Observation Carried Forward (LOCF) were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="2.16"/>
                    <measurement group_id="O2" value="-0.6" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Quality of Life (EuroQoL) Questionnaire-5 Dimensions (EQ-5D) Index Score From Week 24 to Week 49</title>
        <description>The EQ-5D is a Self-reported, 5-item scale to assess health utility (mobility, self-care, usual activities, pain and discomfort, and depression/anxiety). Scoring is on a 3-point scale (1=no health problems, 2=some or moderate problems, 3=major health problems). A preference value Index score is calculated using societal preference developed from a general population-based valuation studies. Index score ranges: United Kingdom (UK): -0.59 to 1.0, United States (US): -0.11 to 1.0, where 1 represents best possible health and 0 represents dead, with &lt;0 interpreted as a health state “worse than dead.” A Quality of Life Health State Score visual analog scale (VAS) was assessed, scores range from 0 to 100. Higher scores indicate better health state. Least Square (LS) Mean values were adjusted for treatment, pooled Investigator, baseline.</description>
        <time_frame>Baseline (Week 24), Week 49</time_frame>
        <population>Participants with a non-missing baseline and at least 1 post-baseline EQ-5D Index Score or VAS score within each group, Last Observation Carried Forward (LOCF) were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>80-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Quality of Life (EuroQoL) Questionnaire-5 Dimensions (EQ-5D) Index Score From Week 24 to Week 49</title>
          <description>The EQ-5D is a Self-reported, 5-item scale to assess health utility (mobility, self-care, usual activities, pain and discomfort, and depression/anxiety). Scoring is on a 3-point scale (1=no health problems, 2=some or moderate problems, 3=major health problems). A preference value Index score is calculated using societal preference developed from a general population-based valuation studies. Index score ranges: United Kingdom (UK): -0.59 to 1.0, United States (US): -0.11 to 1.0, where 1 represents best possible health and 0 represents dead, with &lt;0 interpreted as a health state “worse than dead.” A Quality of Life Health State Score visual analog scale (VAS) was assessed, scores range from 0 to 100. Higher scores indicate better health state. Least Square (LS) Mean values were adjusted for treatment, pooled Investigator, baseline.</description>
          <population>Participants with a non-missing baseline and at least 1 post-baseline EQ-5D Index Score or VAS score within each group, Last Observation Carried Forward (LOCF) were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UK population-based Index Score (n=194, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.01"/>
                    <measurement group_id="O2" value="0.00" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>US population-based Index Score (n=194, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.01"/>
                    <measurement group_id="O2" value="0.00" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Health State Score (N=197, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.60" spread="1.21"/>
                    <measurement group_id="O2" value="3.20" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atomoxetine (Study Periods 2 and 3A)</title>
          <description>40-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 12 weeks during open-label, acute-treatment phase (Study Period 2), and 80-100 mg/day for 12 weeks during double-blind maintenance phase of Study Period 3 (Study Period 3A).</description>
        </group>
        <group group_id="E2">
          <title>Atomoxetine (Study Period 3B)</title>
          <description>40-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 12 weeks during open-label, acute-treatment phase (Study Period 2), and 80-100 mg/day for 12 weeks during double-blind maintenance phase of Study Period 3 (Study Period 3A).
Followed by 80-100 mg/day atomoxetine orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Study Period 3B)</title>
          <description>40-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 12 weeks during open-label, acute-treatment phase (Study Period 2), and 80-100 mg/day for 12 weeks during double-blind maintenance phase of Study Period 3 (Study Period 3A).
Followed by Placebo orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).</description>
        </group>
        <group group_id="E4">
          <title>Atomoxetine (Study Period 4; Open-Label Extension)</title>
          <description>40-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 12 weeks during open-label, acute-treatment phase (Study Period 2), and 80-100 mg/day for 12 weeks during double-blind maintenance phase of Study Period 3 (Study Period 3A) and for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B), followed by a 2 year open label extension (Study Period 4). The open-label extension was optional and only offered to participants living in countries where atomoxetine for the adult ADHD indication had not been approved who had completed the Study Period 3B and were receiving benefit from the drug.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="2011"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diaphragmatic injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Splenic injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bunion operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1611" subjects_at_risk="2011"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="119" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2011"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="90" subjects_affected="83" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="73" subjects_affected="70" subjects_at_risk="2011"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="46" subjects_affected="38" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="30" subjects_affected="29" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="41" subjects_affected="38" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="73" subjects_affected="61" subjects_at_risk="2011"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="99" subjects_affected="93" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="60" subjects_affected="53" subjects_at_risk="2011"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="258"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="368" subjects_affected="342" subjects_at_risk="2011"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="72" subjects_affected="65" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="707" subjects_affected="552" subjects_at_risk="2011"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="266"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="96" subjects_affected="82" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="60" subjects_affected="57" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="292" subjects_affected="262" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="2011"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="87" subjects_affected="80" subjects_at_risk="2011"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="57" subjects_affected="46" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="2011"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="2011"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2011"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="2011"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="266"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="55" subjects_affected="52" subjects_at_risk="2011"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="266"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="258"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="153" subjects_affected="137" subjects_at_risk="2011"/>
                <counts group_id="E2" events="26" subjects_affected="18" subjects_at_risk="266"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="258"/>
                <counts group_id="E4" events="39" subjects_affected="22" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2011"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="2011"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="62" subjects_affected="57" subjects_at_risk="2011"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="266"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="2011"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2011"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="2011"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="2011"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="319" subjects_affected="294" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="2011"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="2011"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="258"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="195" subjects_affected="170" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="482" subjects_affected="347" subjects_at_risk="2011"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="266"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="258"/>
                <counts group_id="E4" events="38" subjects_affected="17" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="46" subjects_affected="26" subjects_at_risk="2011"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="76" subjects_affected="74" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="126" subjects_affected="112" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="35" subjects_affected="34" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="62" subjects_affected="60" subjects_at_risk="2011"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="62" subjects_affected="56" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="2011"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="34" subjects_at_risk="2011"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="209" subjects_affected="177" subjects_at_risk="2011"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="65" subjects_affected="61" subjects_at_risk="2011"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Middle insomnia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="33" subjects_at_risk="2011"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="34" subjects_affected="27" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="82" subjects_affected="71" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="54" subjects_affected="49" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" events="46" subjects_affected="43" subjects_at_risk="2011"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="2011"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ejaculation disorder</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="103" subjects_affected="99" subjects_at_risk="2011"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="2011"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="2011"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="266"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="258"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="196" subjects_affected="180" subjects_at_risk="2011"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Piloerection</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="2011"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="61" subjects_affected="56" subjects_at_risk="2011"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="2011"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

